AUTHOR=Kamel Amir Y. , Emtiazjoo Amir M. , Adkins Lauren , Shahmohammadi Abbas , Alnuaimat Hassan , Pelaez Andres , Machuca Tiago , Pipkin Mauricio , Lee Hyun-wook , Weiner I. David , Chandrashekaran Satish 

TITLE=Hyperammonemia After Lung Transplantation: Systematic Review and a Mini Case Series

JOURNAL=Transplant International

VOLUME=35

YEAR=2022

URL=https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2022.10433

DOI=10.3389/ti.2022.10433

ISSN=1432-2277

ABSTRACT=<p><bold>Background:</bold> Hyperammonemia after lung transplantation (HALT) is a rare but serious complication with high mortality. This systematic review delineates possible etiologies of HALT and highlights successful strategies used to manage this fatal complication.</p><p><bold>Methods:</bold> Seven biomedical databases and grey literature sources were searched using keywords relevant to hyperammonemia and lung transplantation for publications between 1995 and 2020. Additionally, we retrospectively analyzed HALT cases managed at our institution between January 2016 and August 2018.</p><p><bold>Results:</bold> The systematic review resulted in 18 studies with 40 individual cases. The mean peak ammonia level was 769 μmol/L at a mean of 14.1 days post-transplant. The mortality due to HALT was 57.5%. In our cohort of 120 lung transplants performed, four cases of HALT were identified. The mean peak ammonia level was 180.5 μmol/L at a mean of 11 days after transplantation. HALT in all four patients was successfully treated using a multimodal approach with an overall mortality of 25%.</p><p><bold>Conclusion:</bold> The incidence of HALT (3.3%) in our institution is comparable to prior reports. Nonetheless, ammonia levels in our cohort were not as high as previously reported and peaked earlier. We attributed these significant differences to early recognition and prompt institution of multimodal treatment approach.</p>